Cancer Group Presses For Standardized Expanded Access Programs
This article was originally published in The Pink Sheet Daily
A citizen petition by the National Coalition for Cancer Survivorship could inform future FDA guidance on the topic.
You may also be interested in...
Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.
Indian regulators threaten compulsory licensing of the oncologic, but Novartis says it has no plans to end its bid for patent protection.
Patent case for new form of imatinib will now be reviewed by newly formed Intellectual Property Appellate Board.